Wegovy & Ozempic Statistics: Facts on the Weight Loss ‘Wonder Drug’

Almost everyone has heard about Ozempic or Wegovy in the past few years.

Often nicknamed weight loss wonder drugs,' these medications have been making the news for their weight loss and health benefits (and their increasing popularity among celebrities).

However, controversies and horror stories also abound. In this article, we cover all the Wegovy and Ozempic statistics you need to know - the good, the bad, and the bottom line.

So, let's see what these drugs are, how they work, and what the numbers say about Ozempic and Wegovy's impact on weight, health, and market trends.

• Key Wegovy & Ozempic Statistics to Know
• What Are Ozempic & Wegovy and How Do They Work?
  1. The Main Difference Between Ozempic and Wegovy is Dosage
• How Effective Are Ozempic & Wegovy?
  1. Weight Loss Outcomes
  2. Other Health Outcomes
  3. Wegovy & Ozempic Side-Effects Can Range From Mild to Severe
• Global Wegovy & Ozempic Statistics - Use is on the Rise
  1. North America - Biggest Market for Ozempic & Wegovy
     1. A Closer Look at Ozempic and Wegovy in the US
     2. The Explosion of Ozempic in the US Raises Important Concerns
     3. Ozempic Cost in the US Sparked Discussions on Price Discrimination
• Stats About the Impact of Ozempic & Wegovy
  1. The American Public's Perception of Ozempic & Wegovy
  2. Ozempic, Wegovy, and Related Trends
     1. Ozempic and Wegovy Could Impact Individual Food Spending
     2. Weight Loss Drugs Are Changing Beauty Trends
     3. GLP-1 Drugs May Help People Cut Back on More Than Just Food
• Are Ozempic & Wegovy Here to Stay?
  • Key Wegovy & Ozempic Statistics to Know
  • What Are Ozempic & Wegovy and How Do They Work?
    1. The Main Difference Between Ozempic and Wegovy is Dosage
  • How Effective Are Ozempic & Wegovy?
    1. Weight Loss Outcomes
    2. Other Health Outcomes
    3. Wegovy & Ozempic Side-Effects Can Range From Mild to Severe
  • Global Wegovy & Ozempic Statistics - Use is on the Rise
    1. North America - Biggest Market for Ozempic & Wegovy
       1. A Closer Look at Ozempic and Wegovy in the US
       2. The Explosion of Ozempic in the US Raises Important Concerns
       3. Ozempic Cost in the US Sparked Discussions on Price Discrimination
  • Stats About the Impact of Ozempic & Wegovy
    1. The American Public's Perception of Ozempic & Wegovy
    2. Ozempic, Wegovy, and Related Trends
       1. Ozempic and Wegovy Could Impact Individual Food Spending
       2. Weight Loss Drugs Are Changing Beauty Trends
       3. GLP-1 Drugs May Help People Cut Back on More Than Just Food
  • Are Ozempic & Wegovy Here to Stay? Key Wegovy & Ozempic Statistics to Know
    • In 2017, the FDA approved Ozempic for the management of type 2 diabetes. Later, in 2021, the FDA approved Wegovy as a weight loss treatment.
    • Ozempic and Wegovy contain different dosages of the active ingredient Semaglutide.' Ozempic's highest dose is 2 mg, while Wegovy goes up to 2.4 mg.
    • In clinical trials, 2.4 mg of Semaglutide led to a mean -15% loss of body weight over 60 weeks.
    • Clinical trials show that Semaglutide reduces fasting insulin by 32.7% in prediabetic patients, some inflammatory markers by 56.7%, and the risk of death in kidney and heart disease patients with diabetes by 24%.
    • Nearly 16% of trial patients on 0.5 mg of Semaglutide experienced nausea. Around 22-44% of those on 2.4 mg experienced nausea, vomiting, and diarrhea.
    • North America accounts for 59% of Novo Nordisk's global sales. Most of these come from Ozempic - the fourth best-selling drug worldwide in 2023.
    • Between 2020 and 2022, the US saw a 300% increase in prescriptions for weight loss drugs. Ozempic statistics show that, at the end of 2022, the drug accounted for 65% of all prescriptions recorded.
    • As of 2022, Annual Part D Medicare spending on Ozempic amounted to $4.6 billion. Since 2024, 1 in 4 people on Medicare who suffer from obesity could be eligible for Wegovy prescription coverage.
    • Over 50% of Americans are trying to lose weight and around a third show interest in Ozempic and similar drugs.
    • Ozempic prices in the US can be up to ten times higher than in other countries, such as France, Sweden, and the UK.
    What Are Ozempic & Wegovy and How Do They Work?According to the pharmaceutical encyclopedia Drugs.com, Ozempic and Wegovy are different brand names for the injectable anti-diabetes drug, Semaglutide. Both contain the same active substance, but their dosages and recommended uses differ.

    Semaglutide belongs to a class of drugs known as glucagon-like peptide 1, so it's a (GLP-1) agonist.

    These drugs stimulate the pancreas to release insulin, improving blood glucose control and reducing the risk of complications in diabetic patients.

    GLP-1 drugs work through multiple mechanisms
    Source: Genemedics Health Institute

    GLP-1 agonists also affect the central nervous system and gastrointestinal tract, leading to positive shifts in brain chemistry and slower stomach emptying.

    Both of these effects contribute to reduced appetite, potentially leading to reduced caloric intake and weight loss.

    Thus, semaglutide's appetite-suppressing effect makes it a useful drug for weight loss and management when used in conjunction with diet and exercise.

    The Main Difference Between Ozempic and Wegovy is Dosage

    The FDA approved Ozempic in 2017 for type 2 diabetes management. Ozempic comes in Semaglutide dosages ranging from 0.25 to 2 mg, meant to be taken once weekly.

    Obesity in adults is defined as having a BMI of 30 or higher.

    Later, in 2021, the FDA approved Wegovy as a weight loss drug for overweight and obese adults suffering from conditions like hypercholesterolemia, type 2 diabetes, or hypertension.

    In 2024, the FDA approved Wegovy as a preventive treatment in overweight or obese cardiovascular disease patients, citing the drug's usefulness in reducing the risk of heart attack, stroke, and cardiovascular death.

    Wegovy's Semaglutide concentration ranges from 0.25 to 2.4 mg - a higher maximum dose than Ozempic's.

    However, as both contain the same active substance, they seem to show similar benefits in terms of glucose control, weight reduction, and cardiovascular health.

    In fact, in the US, Ozempic statistics show the drug's off-label use for weight loss has led to massive drug shortages before, leaving many struggling to access their diabetes medication.

    How Effective Are Ozempic & Wegovy?

    Semaglutide, found in similar doses in both Ozempic and Wegovy, has been getting a lot of press lately after several studies documented the drug's positive effects on weight loss and chronic disease outcomes.

    Here's what the research shows:

    Weight Loss OutcomesThe Key Takeaway

    When accompanied by lifestyle intervention, high-dose Semaglutide leads to a mean loss of -15% of one's body weight (roughly 34 lbs).

    The weight loss seems to stall at 60 weeks. Overall, this is the equivalent of a slow and gradual weight loss of 0.56 lbs a week.

    However, a body weight reduction of -12% at six months was also observed in the absence of dieting or exercise. A small percentage of people lost -20% or more of their body weight.

    Overall, Semaglutide doesn't look like a weight loss miracle, but study outcomes suggest the drug makes it easier to maintain a caloric deficit with or without actively following a diet.

    A 2021 placebo-controlled trial published in the NEJM found that a once-weekly 2.4 mg Semaglutide injection resulted in a 14.9% reduction in body weight at 68 weeks, with a mean weight loss of 33.7 lbs (vs -2.4% and -5.7 lbs for placebo).

    Weight reduction in Semaglutide vs placebo groups
    Source: NEJM

    The Semaglutide group also lost 5.3 inches in waist circumference, compared to a -1.6-inch reduction in the placebo group.

    The mean starting weight of the Semaglutide group was 231 lbs, and the starting waist circumference was 45.11 inches. But there are two caveats.

    The weight loss seemed to plateau at 60 weeks. The study design also included a lifestyle intervention consisting of a 500-kcal reduction per day and an added 150 minutes of weekly physical activity.

    Additionally, 7% had to discontinue treatment due to adverse effects of Semaglutide.

    A subsequent 2022 study found that overweight or obese patients taking Semaglutide lost 5.9% of their body weight at 3 months and 10.9% at six months into treatment.

    The mean weight loss was -9.7 lbs at 3 months and -14.5 lbs at six months.

    This study was purely observational and didn't assign any lifestyle changes, such as diet or exercise, to the participants.

    Only 25% of participants reported visits with a dietitian, but the researchers found no association between dietitian visits and greater weight loss.

    Source: NCBI

    Although the mean weight loss was nearly 11% at six months, 23.5% of patients achieved a body weight reduction of -15% or more. On the higher end, 7.8% achieved a weight loss of -20% or more.

    Higher doses of Semaglutide (1.7 and 2.4 mg) seemed more effective for weight loss compared to lower doses (0.25-1 mg).

    At 6 months, high-dose patients had a mean weight loss of -12.1%, compared to -9.2% in the lower-dose group.

    In this study, 51.4% of patients reported no side effects, though 2.9% experienced severe adverse effects, and another 8.6% reported moderate symptoms.

    This study had a sample of 175 participants at the start, though only 102 remained at six months. That said, we also have a longer 2022 study that lasted two years.

    The STEP 5 trial had 304 participants assigned to either a once-weekly injection of 2.4 mg Semaglutide or a placebo. The mean starting weight of the participants was 233.7 lbs, and the mean BMI was 38.5.

    Those on Semaglutide lost more weight than the placebo controls
    Source: Nature Medicine

    From baseline to week 104, the Semaglutide group saw a -15.2% reduction in body weight (vs. -2.6% for placebo). Those on Semaglutide lost -5.6 inches in waist circumference, compared to -2 inches for placebo.

    Again, the weight loss seemed to stall at 60 weeks. Like in the previous NEJM study, participants were counseled to reduce their calories by 500 a day and exercise 150 minutes a week.

    Roughly 82% of those on semaglutide experienced gastrointestinal issues, mostly mild to moderate in severity; only 3.9% had to discontinue treatment.

    Other Health Outcomes

    In the STEP 5 trial, those on Semaglutide also had greater reductions in health markers like:

    • Blood pressure
    • HbA1c (the average blood glucose level over 3 months)
    • Fasting glucose
    • Fasting insulin
    • C-reactive protein (an inflammatory marker)
    • Total and LDL cholesterol
    • Triglycerides

    Those on Semaglutide saw a -32.7% reduction in fasting serum insulin at 104 weeks (vs. -7.2% for placebo). Nearly 80% of prediabetic patients on Semaglutide achieved normal blood glucose at week 104.

    Triglycerides and C-reactive protein also dropped -19% and -56.7%, respectively, in the intervention group (vs. +3.7% and -7.8% for placebo).

    The Semaglutide group saw a reduction in fatal cardiovascular events
    Source: NEJM

    Another 2023 placebo-controlled trial found that Semaglutide positively impacts cardiovascular outcomes in non-diabetic adults with overweight or obesity.

    The study found that, after a mean follow-up of 39.8 months, the group on a weekly 2.4 mg Semaglutide dose experienced fewer deaths from cardiovascular events, nonfatal myocardial infarctions, and nonfatal strokes (6.5% of the intervention vs 8% of the placebo group).

    A 2023 meta-analysis of 17 Semaglutide trials looking specifically at type 2 diabetes patients had similar findings.

    Compared to the placebo, Semaglutide led to a statistically significant reduction in HbA1c, body weight, fasting glucose, and blood pressure in diabetic patients.

    According to a 2024 Reuters report on Novo Nordisk's kidney trial, Semaglutide (1.0 mg once-weekly) also delays the progression of chronic kidney disease in diabetic patients.

    This latest study found that Semaglutide reduces the risk of death from major adverse kidney and cardiac events by 24% in this population.

    In short, Semaglutide's impact on glucose control and weight seems to have a cascade of positive effects on other health markers and disease outcomes.

    But, as with any pharmaceutical drug, there are side effects to consider.

    Wegovy & Ozempic Side-Effects Can Range From Mild to Severe

    According to Ozempic statistics provided by the FDA, the most common side effects of Ozempic, reported in 5% or more of patients, include:

    • Nausea and vomiting
    • Diarrhea or constipation
    • Abdominal pain.

    Nausea was reported in nearly 16% of patients on the 0.5 mg dose in placebo-controlled trials. More severe but rare side effects observed in Ozempic trials include:

    • Pancreatitis (inflammation of the pancreas)
    • Diabetic retinopathy complications
    • Hypoglycemia in diabetes patients taking other glucose-lowering drugs
    • Acute kidney injury
    • Allergic reactions

    Wegovy's most common adverse reactions, observed in over 10% of patients in clinical trials, include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue.

    Nausea, vomiting, and diarrhea were the most common adverse reactions in both adults and minors over 12 years old, occurring in 22-44% of patients on a 2.4 mg dose.

    Other common side effects noticed in 3% or more of patients included:

    • Indigestion
    • Dizziness
    • Abdominal distension
    • Diabetic hypoglycemia
    • Flatulence
    • Gastroesophageal reflux
    • Gastritis
    • Hair loss

    Severe but rare adverse effects of Wegovy include:

    • Acute pancreatitis
    • Acute gallbladder disease
    • Acute kidney injury
    • Diabetic retinopathy complications
    • Allergic reactions
    • Increased heart rate
    • Suicidal ideation
    Both Ozempic and Wegovy come with a black box warning for the risk of thyroid C-cell tumors, an effect observed in rodent studies. The risk of Medullary Thyroid Carcinoma (MTC) in humans is still unknown.Global Wegovy & Ozempic Statistics - Use is on the Rise

    Novo Nordisk, the producer of Ozempic and Wegovy, registered record sales last year. Although first launched in 2021, Wegovy's popularity exploded rapidly.

    In 2023, the obesity drug saw a nearly fourfold difference in sales compared to the end of 2022.

    Source: Statista

    And that's just Wegovy. According to 2023 Statista data, 75% of Novo Nordisk's sales come from diabetes care, which suggests Ozempic is significantly more popular.

    However, Novo Nordisk's share of sales for obesity therapies also doubled between 2022 and 2023, with Statista showing Ozempic was the fourth best-selling drug worldwide in 2023, registering $13.9b in sales.

    Other Ozempic statistics show remarkable projected growth in 2024. Ozempic is set to become the second best-selling drug worldwide in 2024, and its 2024 sales are now estimated at $16.1 billion.

    Source: Google Trends

    As seen on Google Trends, searches for Ozempic have been rapidly increasing since 2021-the US has the largest search volume for Ozempic in 2024, followed by Canada, Australia, Ireland and Brazil.

    North America - Biggest Market for Ozempic & Wegovy

    Since 2022, the share of Novo Nordisk sales in North America surpassed the rest of the world combined. In 2023, NA accounts for 59% of global sales, followed by:

    • 22% in EMEA (Europe, Middle East, and Africa) and
    • 7% in China.
    Source: Statista

    Ozempic is by far the most popular of the two drugs. In 2022, Ozempic saw the largest and fastest growth among all pharmaceuticals in Canada, registering an 84% increase in sales.

    But the US remains by far the largest market for Ozempic and Wegovy.

    A Closer Look at Ozempic and Wegovy in the US

    According to the Washington Post, prescriptions for Ozempic and other similar drugs quadrupled in the US between Q1 and Q4 of 2020.

    Zooming out further, there was an overall 300% increase in GLP-1 prescriptions between early 2020 and the end of 2022.

    During the last three months of 2022, physicians wrote over 9 million prescriptions for Ozempic and similar drugs.

    Ozempic statistics also show that diabetes drugs accounted for over 65% of the total prescriptions at the end of 2022; many of these were off-label and likely for weight loss.

    Again in 2023, sales went up by 58% for Ozempic and 363% for Wegovy in the first half of the year, according to CNBC.

    The Explosion of Ozempic in the US Raises Important Concerns

    The rapid increase in demand for Ozempic and Wegovy led to drug shortages which are still ongoing today.

    And with off-label use of GLP-1 drugs only increasing, this could spell trouble for the US medical system, particularly in diabetes care. These effects are already apparent.

    USA Today's coverage of a 2023 Trilliant Health report shows that Ozempic prescriptions went up 481% in Cleveland and 351% in Seattle since Wegovy's approval in 2021.

    However, Boston and Philadelphia, where rates of diabetes, obesity, and cardiovascular disease are statistically higher, only saw increases of 79% and 80%, respectively.

    The data supports the idea that many Ozempic prescriptions aren't going to diabetic patients.

    Wegovy's approval for weight loss likely influenced Ozempic's popularity as an off-label appetite suppressant, as Ozempic is roughly $300 cheaper for a similar dose.

    And with the FDA recently extending Wegovy's list of approved uses, we'll likely see more Semaglutide-based drug prescriptions in the near future.

    More Americans could now be eligible for Wegovy prescriptions
    Source: KFF

    Since the FDA approved the use of Wegovy to reduce the risk of heart attack and stroke in overweight and obese patients, 1 in 4 people on Medicare who are overweight or obese could be eligible for prescription coverage, as per KFF's latest analysis.

    However, the steep price of Semaglutide-based medications and their impact on the American healthcare system remains a concern.

    In March 2024, Senator Bernie Sanders, Chairman of the HELP Committee, went on record to state:

    This outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system.Bernie Sanders

    According to 2024 estimates, Medicare spending on three weight loss drugs (including Ozempic) went from $57 million in 2018 to $5.7 billion in 2022.

    Ozempic had the largest share of Medicare spending among all weight loss drugs and was sixth among the 10 best-selling drugs in Medicare Part D overall.

    As of 2022, Part D annual spending on Ozempic amounted to $4.6 billion, according to KFF.

    Ozempic Cost in the US Sparked Discussions on Price Discrimination

    The numbers don't lie; Novo Nordisk has seen great success in the American market. However, the Danish company recently came under fire for its exorbitant pricing.

    The US has the highest prices for Ozempic and Wegovy
    Source: KFF

    The list price of Ozempic in the US is $936; Wegovy is even pricier, at $1,349. According to recent data, prices can be up to 10 times lower in other countries.

    In Canada, Ozempic costs $147. In Sweden, France, and the UK, the drug is less than $100. Similarly, the price of Wegovy in the US is four times higher than in Germany.

    Stats About the Impact of Ozempic & WegovyThe US will likely remain the biggest market for GLP-1 drugs.

    As of 2022, Novo Nordisk has a 32% share of the global diabetes drugs market.

    Based on current Ozempic statistics, the Semaglutide-based drug could remain the best-selling diabetes medication worldwide in 2028 and the fifth best-selling medication overall.

    Statista's projections suggest the anti-diabetes drug market could reach a global revenue of nearly $90 billion in 2028, with the US accounting for nearly 48% of the total.

    As per a 2023 JP Morgan report, around 10-12% of type 2 diabetics in the US are currently on a GLP-1 medication like Ozempic.

    But by the end of the decade, 9% of the overall US population could be on a GLP-1 medication, half of them for obesity treatment.

    In fact, according to a 2020 Statista survey, over 50% of American respondents said they were trying to lose weight.

    According to the latest surveys, a significant share of Americans pursuing weight loss are now interested in Ozempic and other similar drugs.

    The American Public's Perception of Ozempic & Wegovy

    In 2023, nearly a third of surveyed Americans were interested in GLP-1 drugs like Ozempic for weight loss, and a third or more believe that they're safe and effective for losing or keeping the body weight off.

    Source: Statista

    Furthermore, according to a 2024 Pew Research Center survey:

    • 53% of Americans see weight loss drugs as a suitable option for people suffering from obesity
    • 65% believe willpower alone is usually not enough for losing and keeping weight off

    Certain demographics could be more likely to see Ozempic and other weight loss drugs favorably, at least based on diverging views about willpower and weight loss.

    The survey found that 71% of overweight adults viewed willpower as insufficient for weight loss, compared to roughly 56% of healthy-weight adults.

    Similarly, 71% of women and 71% of adults over 50 claimed willpower is not enough to lose weight (compared to 59% of men and 55% of those under 30).

    Still, not many are optimistic about the weight loss results of such drugs. A third of respondents thought these medications won't do much, if anything, for America's obesity problem.

    It seems diet and exercise are still king, despite a growing demand for weight loss drugs in the US. A majority of the American public believes diet, in particular, contributes a great deal' to someone's weight.

    Diet and exercise are the most cited factors for weight gain or loss
    Source: Pew Research

    In the same Pew Research survey, only 16% thought GLP-1 drugs would have a serious impact on obesity.

    Indeed, in most clinical trials, Semaglutide dosages similar to those in Ozempic and Wegovy only produced a mean weight loss of 34 lbs in overweight or obese subjects.

    However, even minimal weight loss can bring significant health benefits to obese and overweight patients.

    Ozempic, Wegovy, and Related Trends

    Beyond their impact on weight, health, and the American healthcare budget, weight loss drugs like Ozempic and Wegovy have also been influencing other trends. Here are some of the most interesting findings.

    Ozempic and Wegovy Could Impact Individual Food Spending

    A 2023 article published on eMarketer highlights findings that those on GLP-1 drugs bought 8% less food for at-home consumption in 2023. However, other studies found no change in purchasing behavior.

    Another report covered in the article estimates that a 10% growth in GLP-1 adoption would only lead to a 0.5% reduction in food sale volumes per year over a five-year period.

    The appetite-suppressing drug could have wider-reaching implications
    Source: CNN

    While there might be a trend towards lower food spending at an individual level, the jury is still out on the actual impacts of Ozempic on the food industry.

    Weight Loss Drugs Are Changing Beauty Trends

    Right now, it's the beauty and fashion sector seeing the biggest impacts of the GLP-1 craze. For example, searches for ozempic face' peaked at the beginning of 2023 and again in 2024.

    At the same time, according to eMarketer, social media searches for contouring are down 10.6%.

    Source: Google Trends

    According to a recent Forbes article, we might see an uptick in treatments like fillers and microneedling to combat cosmetic issues caused by rapid weight loss.

    CNN also gives some insight into the changing fashion industry, such as the number of mid- and plus-size models falling by 24% in the 2023 Fall-Winter season compared to the Spring-Summer season.

    The article partly attributes this change to Ozempic's influence on public perception of weight loss and body image trends. However, we're yet to see a change in consumer demand for bigger sizes.

    Global and US Google searches for plus size fashion' have been relatively stable since 2021.

    GLP-1 Drugs May Help People Cut Back on More Than Just Food

    Some anecdotes also suggest Ozempic and Wegovy could lead to changes in the consumption of alcohol and nicotine, as well as reduce addictive behaviors like gambling and online shopping.

    Ozempic might cut more than just food cravings
    Source: HealthDigest

    A 2024 survey found that GLP-1 drugs cut the percentage of weekly smokers in the survey from 40% to 24%.

    More than 50% of respondents also reduced their alcohol intake, and 18% said they'd give up alcohol entirely since starting the medication.

    Are Ozempic & Wegovy Here to Stay?

    The 2022 Ozempic and Wegovy shortages are still ongoing, and demand for the drugs is at an all-time high.

    Currently, Novo Nordisk dominates the diabetes drugs market, although many Ozempic prescriptions are off-label and likely used for weight loss purposes.

    With the global number of overweight and obese adults projected to reach 3.3 billion by 2035, the market for GLP-1 drugs, including Ozempic, is set to continue growing.

    However, the competition has also increased, with US-based drugmaker Eli Lilly entering the market with its own weight-loss drug. Novo Nordisk is also developing a new injection expected to outperform Wegovy.

    It seems a new generation of weight-loss drugs is underway. In some form or another, Ozempic, Wegovy, and other competing weight-loss drugs might stick around for a while.

    Click to Expand and View Sources
    • User's Guide To Mechanism Of Action And Clinical Use Of Glp-1 Receptor Agonists (NCBI)
    • How Does Semaglutide Work For Weight Loss? (Drugs.com)
    • Ozempic Vs Wegovy: What's The Difference Between Them? (Drugs.com)
    • FDA Approves Novo Nordisk Diabetes Drug Ozempic (Reuters)
    • FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 (FDA)
    • FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (FDA)
    • People With Diabetes Struggle To Find Ozempic As It Soars In Popularity As A Weight Loss Aid (NBC News)
    • Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM)
    • Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity (NCBI)
    • Two-Year Effects Of Semaglutide In Adults With Overweight Or Obesity: The Step 5 Trial (Nature Medicine)
    • Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (NEJM)
    • Efficacy And Tolerability Of The Subcutaneous Semaglutide For Type 2 Diabetes Patients: An Updated Systematic Review And Meta-Analysis (BMC)
    • Novo Kidney Trial Finds Ozempic Cuts Cardiac Deaths In Diabetics (Reuters)
    • Ozempic (Semaglutide) Injection, For Subcutaneous Use (FDA)
    • Diabetic Retinopathy - Symptoms & Causes (Mayo Clinic)
    • WEGOVY (Semaglutide) Injection, For Subcutaneous Use (FDA)
    • Quarterly Sales of Novo Nordisk's Wegovy in 2022 and 2023 (Statista)
    • Novo Nordisk's Sales Distribution By Therapeutic Area From 2021 to 2023 (Statista)
    • Leading Pharmaceutical Products By Sales Worldwide in 2023 (Statista)
    • Leading Drugs Worldwide Based On Projected 2024 Sales (Statista)
    • Novo Nordisk's Sales Distribution By World Region in 2023 (Statista)
    • Growth Among Leading 10 Pharmaceutical Products Based On Sales in Canada in 2022 (Statista)
    • Prescriptions for Ozempic and Similar Drugs Have Skyrocketed, Data Shows (The Washington Post)
    • Ozempic, Wegovy Drug Prescriptions Hit 9 Million, Surge 300% In Under Three Years (CNBC)
    • How Ozempic and Wegovy Turned Novo Nordisk Into A $400 Billion Company (CNBC)
    • Drug Shortages At Highest Since 2014: Chemo Drugs, Wegovy, Adhd Medications Affected (USA Today)
    • These 15 Metro Areas Saw Biggest Jumps In Ozempic Use. They Might Not Be Where You Expect (USA Today)
    • A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity (KFF)
    • NEWS: Sanders Statement on Outrageous Cost of Ozempic (US Senate)
    • Weight Loss Drugs Like Wegovy Have Taken The Country By Storm. But Who Can Afford Them? (USA Today)
    • Ozempic Maker Novo Nordisk Facing Pressure As Study Finds $1,000 Appetite Suppressant Can Be Made For Just $5 (Fortune)
    • Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries (KFF)
    • Anti-Diabetes Drugs - Worldwide (Statista)
    • Projected Best-Selling Pharmaceutical Drugs Worldwide In 2028 (Statista)
    • The Increase In Appetite For Obesity Drugs (J.P. Morgan)
    • Percentage of the Population In Select Countries Worldwide Who Were Trying To Lose Weight In 2020 (Statista)
    • Percentage of Adults In The United States Who Felt They Needed To Lose Weight Who Were Interested In Trying to Select
    • Weight Loss Methods As Of 2023 (Statista)
    • Percentage of Adults In The United States Who Said They Believe The Following Weight Loss Methods Are Safe And Effective For Losing Weight As Of 2023 (Statista)
    • How Americans View Weight-Loss Drugs and Their Potential Impact on Obesity in the U.S. (Pew Research Center)
    • In Obese Patients, 5 Percent Weight Loss Has Significant Health Benefits (Washington University School of Medicine)
    • How the Ozempic Effect Is - And Isn't - Changing Consumer Behavior (eMarketer)
    • GLP-1 Diabetes And Weight-Loss Drug Side Effects: Ozempic Face" And More (Harvard Health)
    • How Ozempic Can Change Food Beauty And Apparel Businesses (Forbes)
    • A Definitive Backslide.' Inside Fashion's Worrying Runway Trend (CNN)
    • Ozempic, Wegovy May Curb Drinking, Smoking, And Other Addictive Behaviors - Here's What We Know (CNBC)
    • People on Ozempic Find That They're Drinking and Smoking Less Too (Yahoo News UK)

    The post Wegovy & Ozempic Statistics: Facts on the Weight Loss Wonder Drug' appeared first on The Tech Report.